| pubmed-article:18239614 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18239614 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:18239614 | lifeskim:mentions | umls-concept:C0033860 | lld:lifeskim |
| pubmed-article:18239614 | lifeskim:mentions | umls-concept:C0079091 | lld:lifeskim |
| pubmed-article:18239614 | lifeskim:mentions | umls-concept:C1442792 | lld:lifeskim |
| pubmed-article:18239614 | lifeskim:mentions | umls-concept:C1174995 | lld:lifeskim |
| pubmed-article:18239614 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:18239614 | lifeskim:mentions | umls-concept:C0332206 | lld:lifeskim |
| pubmed-article:18239614 | lifeskim:mentions | umls-concept:C1710548 | lld:lifeskim |
| pubmed-article:18239614 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:18239614 | pubmed:dateCreated | 2008-4-14 | lld:pubmed |
| pubmed-article:18239614 | pubmed:abstractText | Efalizumab (anti-CD11a) interferes with LFA-1/ICAM-1 binding and inhibits several key steps in psoriasis pathogenesis. This study characterizes the effects of efalizumab on T-cell activation responses and expression of surface markers on human circulating psoriatic T cells during a therapeutic trial. Our data suggest that efalizumab may induce a unique type of T-cell hyporesponsiveness, directly induced by LFA-1 binding, which is distinct from conventional anergy described in animal models. Direct activation of T cells through different activating receptors (CD2, CD3, CD3/28) is reduced, despite T cells being fully viable. This hyporesponsiveness was spontaneously reversible after withdrawal of the drug, and by IL-2 in vitro. In contrast to the state of anergy, Ca(+2) release is intact during efalizumab binding. Furthermore, lymphocyte function-associated antigen-1 (LFA-1) blockade resulted in an unexpected downregulation of a broad range of surface molecules, including the T-cell receptor complex, co-stimulatory molecules, and integrins unrelated to LFA-1, both in the peripheral circulation and in diseased skin tissue. These observations provide evidence for the mechanism of action of efalizumab. The nature of this T-cell hyporesponsiveness suggests that T-cell responses may be reduced during efalizumab therapy, but are reversible after ceasing efalizumab treatment. | lld:pubmed |
| pubmed-article:18239614 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18239614 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18239614 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18239614 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18239614 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18239614 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18239614 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18239614 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18239614 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18239614 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18239614 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18239614 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18239614 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18239614 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18239614 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18239614 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18239614 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18239614 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18239614 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18239614 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18239614 | pubmed:month | May | lld:pubmed |
| pubmed-article:18239614 | pubmed:issn | 1523-1747 | lld:pubmed |
| pubmed-article:18239614 | pubmed:author | pubmed-author:KruegerJames... | lld:pubmed |
| pubmed-article:18239614 | pubmed:author | pubmed-author:KikuchiToyoko... | lld:pubmed |
| pubmed-article:18239614 | pubmed:author | pubmed-author:DummerWolfgan... | lld:pubmed |
| pubmed-article:18239614 | pubmed:author | pubmed-author:Guttman-Yassk... | lld:pubmed |
| pubmed-article:18239614 | pubmed:author | pubmed-author:VugmeysterYul... | lld:pubmed |
| pubmed-article:18239614 | pubmed:author | pubmed-author:GilleaudeauPa... | lld:pubmed |
| pubmed-article:18239614 | pubmed:author | pubmed-author:HowellKathyK | lld:pubmed |
| pubmed-article:18239614 | pubmed:author | pubmed-author:ChamianFrance... | lld:pubmed |
| pubmed-article:18239614 | pubmed:author | pubmed-author:LeeEdmundE | lld:pubmed |
| pubmed-article:18239614 | pubmed:author | pubmed-author:LowesMichelle... | lld:pubmed |
| pubmed-article:18239614 | pubmed:author | pubmed-author:KagenMarkM | lld:pubmed |
| pubmed-article:18239614 | pubmed:author | pubmed-author:BodarySarah... | lld:pubmed |
| pubmed-article:18239614 | pubmed:author | pubmed-author:HunteBrisdell... | lld:pubmed |
| pubmed-article:18239614 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18239614 | pubmed:volume | 128 | lld:pubmed |
| pubmed-article:18239614 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18239614 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18239614 | pubmed:pagination | 1182-91 | lld:pubmed |
| pubmed-article:18239614 | pubmed:meshHeading | pubmed-meshheading:18239614... | lld:pubmed |
| pubmed-article:18239614 | pubmed:meshHeading | pubmed-meshheading:18239614... | lld:pubmed |
| pubmed-article:18239614 | pubmed:meshHeading | pubmed-meshheading:18239614... | lld:pubmed |
| pubmed-article:18239614 | pubmed:meshHeading | pubmed-meshheading:18239614... | lld:pubmed |
| pubmed-article:18239614 | pubmed:meshHeading | pubmed-meshheading:18239614... | lld:pubmed |
| pubmed-article:18239614 | pubmed:meshHeading | pubmed-meshheading:18239614... | lld:pubmed |
| pubmed-article:18239614 | pubmed:meshHeading | pubmed-meshheading:18239614... | lld:pubmed |
| pubmed-article:18239614 | pubmed:meshHeading | pubmed-meshheading:18239614... | lld:pubmed |
| pubmed-article:18239614 | pubmed:meshHeading | pubmed-meshheading:18239614... | lld:pubmed |
| pubmed-article:18239614 | pubmed:meshHeading | pubmed-meshheading:18239614... | lld:pubmed |
| pubmed-article:18239614 | pubmed:meshHeading | pubmed-meshheading:18239614... | lld:pubmed |
| pubmed-article:18239614 | pubmed:meshHeading | pubmed-meshheading:18239614... | lld:pubmed |
| pubmed-article:18239614 | pubmed:meshHeading | pubmed-meshheading:18239614... | lld:pubmed |
| pubmed-article:18239614 | pubmed:meshHeading | pubmed-meshheading:18239614... | lld:pubmed |
| pubmed-article:18239614 | pubmed:meshHeading | pubmed-meshheading:18239614... | lld:pubmed |
| pubmed-article:18239614 | pubmed:meshHeading | pubmed-meshheading:18239614... | lld:pubmed |
| pubmed-article:18239614 | pubmed:meshHeading | pubmed-meshheading:18239614... | lld:pubmed |
| pubmed-article:18239614 | pubmed:meshHeading | pubmed-meshheading:18239614... | lld:pubmed |
| pubmed-article:18239614 | pubmed:meshHeading | pubmed-meshheading:18239614... | lld:pubmed |
| pubmed-article:18239614 | pubmed:meshHeading | pubmed-meshheading:18239614... | lld:pubmed |
| pubmed-article:18239614 | pubmed:meshHeading | pubmed-meshheading:18239614... | lld:pubmed |
| pubmed-article:18239614 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18239614 | pubmed:articleTitle | Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness. | lld:pubmed |
| pubmed-article:18239614 | pubmed:affiliation | Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York 10065, USA. | lld:pubmed |
| pubmed-article:18239614 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18239614 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:18239614 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18239614 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18239614 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18239614 | lld:pubmed |
